Covid-19 vaccine for 5- to 11-year-olds is safe and shows 'robust' antibody response, Pfizer says
CNN
A Phase 2/3 trial of Pfizer/BioNTech's two-dose Covid-19 vaccine for children ages 5 to 11 showed it is safe and generated a "robust" antibody response.
These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon.
The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. This trials used a 10-microgram dose -- smaller than the 30-microgram dose that has been used for those 12 and older.
Venezuelan authorities are investigating opposition leader Maria Corina Machado for alleged treason after she expressed support for a US bipartisan bill that seeks to block Washington from doing business with any entity that has commercial ties with the government of Venezuela’s President Nicolas Maduro.
Tulsi Gabbard, Donald Trump’s pick to lead the intelligence community, was briefly placed on a Transportation Security Administration list that prompts additional security screening before flights after her overseas travel patterns and foreign connections triggered a government algorithm earlier this year, three sources familiar with the matter told CNN.